TIBSOVO® (ivosidenib) Now Available from Onco360 for the Treatment of Adult Patients with IDH1-mutant Acute Myeloid Leukemia or Previously Treated, IDH1-mutant Metastatic CholangiocarcinomaIDH1-mutant Metastatic Cholangiocarcinoma
15 Sep 2022
LOUISVILLE, Ky.--(BUSINESS WIRE)-- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Servier Pharmaceuticals to be a specialty pharmacy partner for TIBSOVO® (ivosidenib), which is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with newly diagnosed acute myeloid leukemia (AML) in combination with azacitidine or as monotherapy in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, relapsed or refractory AML, or locally advanced or metastatic cholangiocarcinoma that has been previously treated.
“Onco360 is honored to partner with Servier Pharmaceuticals and become a specialty pharmacy provider for TIBSOVO® patients,” said Benito Fernandez, Chief Commercial Officer, Onco360. “We are dedicated to supporting the highly specialized needs of patients battling IDH1-mutant AMLIDH1-mutant AML or cholangiocarcinoma across the United States.”
According to the National Cancer InstituteCancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, it is estimated that 20,050 new cases of AML will be diagnosed in 2022 in the United States with a corresponding 11,540 deaths in 2022. Approximately 6-9% of AML cases are found to have IDH1 mutations. The median age at the time of initial AML diagnosis is 68 years. The five-year overall survival for AML patients is only 30.5%.1,2
According to the American Cancer Society, approximately 8,000 patients are diagnosed with cholangiocarcinoma, a bile duct cancer, on an annual basis in the United States. Approximately 13% of cholangiocarcinoma cases are found to have IDH1 mutations. The average age at the time of initial cholangiocarcinoma diagnosis is 70-72 years old dependent upon tumor location. The five-year overall survival for cholangiocarcinoma patients, regardless of cancer stage, is only 9-10% dependent upon tumor location.3,4
TIBSOVO® is commercialized by Servier Pharmaceuticals. Please see the full prescribing information for TIBSOVO® at Tibsovopro.com.
About Onco360 Oncology Pharmacy:
Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.
References:
1) All statistics from Acute Myeloid Leukemia — Cancer Stat Facts accessed on 8/15/2022
2) All statistics from aml.pdf (nccn.org) accessed on 8/15/22
3) All statistics from Statistics About Bile Duct Cancer | CholangiocarcinomaCholangiocarcinoma Stats accessed on 8/15/22
4) All statistics from hepatobiliary.pdf (nccn.org) accessed on 8/15/22
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.